AU2017281082B2 - Aldose reductase inhibitors and methods of use thereof - Google Patents

Aldose reductase inhibitors and methods of use thereof Download PDF

Info

Publication number
AU2017281082B2
AU2017281082B2 AU2017281082A AU2017281082A AU2017281082B2 AU 2017281082 B2 AU2017281082 B2 AU 2017281082B2 AU 2017281082 A AU2017281082 A AU 2017281082A AU 2017281082 A AU2017281082 A AU 2017281082A AU 2017281082 B2 AU2017281082 B2 AU 2017281082B2
Authority
AU
Australia
Prior art keywords
compound
hydrogen
alkyl
pharmaceutically acceptable
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017281082A
Other languages
English (en)
Other versions
AU2017281082A1 (en
Inventor
Donald W. Landry
Andrew Wasmuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of AU2017281082A1 publication Critical patent/AU2017281082A1/en
Application granted granted Critical
Publication of AU2017281082B2 publication Critical patent/AU2017281082B2/en
Priority to AU2021203801A priority Critical patent/AU2021203801B2/en
Priority to AU2023204218A priority patent/AU2023204218B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cosmetics (AREA)
AU2017281082A 2016-06-21 2017-06-21 Aldose reductase inhibitors and methods of use thereof Active AU2017281082B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021203801A AU2021203801B2 (en) 2016-06-21 2021-06-09 Aldose reductase inhibitors and methods of use thereof
AU2023204218A AU2023204218B2 (en) 2016-06-21 2023-06-30 Aldose reductase inhibitors and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662352784P 2016-06-21 2016-06-21
US62/352,784 2016-06-21
PCT/US2017/038505 WO2017223179A1 (en) 2016-06-21 2017-06-21 Aldose reductase inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021203801A Division AU2021203801B2 (en) 2016-06-21 2021-06-09 Aldose reductase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2017281082A1 AU2017281082A1 (en) 2018-12-06
AU2017281082B2 true AU2017281082B2 (en) 2021-03-18

Family

ID=60783884

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017281082A Active AU2017281082B2 (en) 2016-06-21 2017-06-21 Aldose reductase inhibitors and methods of use thereof
AU2021203801A Active AU2021203801B2 (en) 2016-06-21 2021-06-09 Aldose reductase inhibitors and methods of use thereof
AU2023204218A Active AU2023204218B2 (en) 2016-06-21 2023-06-30 Aldose reductase inhibitors and methods of use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021203801A Active AU2021203801B2 (en) 2016-06-21 2021-06-09 Aldose reductase inhibitors and methods of use thereof
AU2023204218A Active AU2023204218B2 (en) 2016-06-21 2023-06-30 Aldose reductase inhibitors and methods of use thereof

Country Status (22)

Country Link
US (6) US10150779B2 (OSRAM)
EP (3) EP3352754B1 (OSRAM)
JP (4) JP6895464B2 (OSRAM)
CN (2) CN109310674B (OSRAM)
AU (3) AU2017281082B2 (OSRAM)
CA (1) CA3025081A1 (OSRAM)
DK (2) DK3352754T3 (OSRAM)
ES (2) ES2966094T3 (OSRAM)
FI (1) FI3757107T3 (OSRAM)
HR (2) HRP20231563T1 (OSRAM)
HU (2) HUE064911T2 (OSRAM)
IL (3) IL304979A (OSRAM)
LT (2) LT3352754T (OSRAM)
MX (2) MX391561B (OSRAM)
NZ (1) NZ748506A (OSRAM)
PL (1) PL3757107T3 (OSRAM)
PT (2) PT3352754T (OSRAM)
RS (1) RS61239B1 (OSRAM)
SG (2) SG11201810642XA (OSRAM)
SI (2) SI3757107T1 (OSRAM)
WO (1) WO2017223179A1 (OSRAM)
ZA (1) ZA201808506B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
PT3352754T (pt) * 2016-06-21 2020-12-07 Univ Columbia Inibidores da aldose redutase e métodos de seu uso
IL272246B1 (en) * 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
WO2020167937A1 (en) * 2019-02-12 2020-08-20 Applied Therapeutics, Inc. Methods for treating cutaneous aging
SG11202110590PA (en) 2019-04-01 2021-10-28 Applied Therapeutics Inc Inhibitors of aldose reductase
MX2021013511A (es) 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.
CA3153108A1 (en) * 2019-10-08 2021-04-15 Riccardo Perfetti Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency
WO2021202523A1 (en) 2020-03-31 2021-10-07 Applied Therapeutics, Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
CA3176768A1 (en) * 2020-05-01 2021-11-04 Shoshana SHENDELMAN Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
US20240033263A1 (en) * 2021-03-18 2024-02-01 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications
WO2025219948A1 (en) 2024-04-17 2025-10-23 Assia Chemical Industries Ltd. Crystalline forms of govorestat

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293371A1 (en) * 2002-06-14 2006-12-28 Takeda Pharmaceuticals North America, Inc. Prodrug and process for producing the same
US20130225592A1 (en) * 2010-07-16 2013-08-29 Andrew WASMUTH Aldose reductase inhibitors and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189272A3 (en) * 1985-01-17 1987-08-19 Fujisawa Pharmaceutical Co., Ltd. New furanone derivatives, processes for preparation thereof and use thereof
ES2032749T3 (es) 1985-11-07 1993-03-01 Pfizer Inc. Acidos oxoftalazinil-aceticos heterociclicos.
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
CA1299178C (en) 1985-11-07 1992-04-21 Banavara Lakshmana Mylari Heterocyclic oxophtalazinyl acetic acids
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
WO1989006651A1 (en) * 1988-01-19 1989-07-27 Pfizer Inc. 1h-indazole-3-acetic acids as aldose reductase inhibitors
US4954629A (en) 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5304557A (en) 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
NZ254550A (en) * 1992-09-28 1997-08-22 Pfizer Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications
NZ313896A (en) 1995-08-28 2000-08-25 American Home Prod 4-formyl-2-(naphthalenylmethyl)phenoxyacetic acids or salts and antihyperglycemic agents for the treatment of diabetes mellitus
US6169087B1 (en) 1997-09-23 2001-01-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
AU774929B2 (en) 1998-03-31 2004-07-15 Institutes For Pharmaceutical Discovery, Llc, The Substituted indolealkanoic acids
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
NZ528406A (en) 2001-03-30 2004-03-26 Pfizer Prod Inc Pyridazinone aldose reductase inhibitors
ES2274201T3 (es) 2002-01-23 2007-05-16 Eli Lilly And Company Agonistas del receptor de melanocortina.
US20040047919A1 (en) 2002-06-13 2004-03-11 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20070021366A1 (en) 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
WO2006078717A2 (en) 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
CN101143868A (zh) 2007-09-04 2008-03-19 北京理工大学 醛糖还原酶抑制剂结构及用途
WO2012009553A1 (en) * 2010-07-16 2012-01-19 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
CN102512407B (zh) 2011-11-23 2014-05-21 中山大学 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
PT3352754T (pt) 2016-06-21 2020-12-07 Univ Columbia Inibidores da aldose redutase e métodos de seu uso
US11329472B2 (en) 2018-07-20 2022-05-10 Texas Instruments Incorporated Methods and apparatus to prevent undesired triggering of short circuit or over current protection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293371A1 (en) * 2002-06-14 2006-12-28 Takeda Pharmaceuticals North America, Inc. Prodrug and process for producing the same
US20130225592A1 (en) * 2010-07-16 2013-08-29 Andrew WASMUTH Aldose reductase inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PUBCHEM, (2015-02-12), Database accession no. 227698804 *

Also Published As

Publication number Publication date
US20230312599A1 (en) 2023-10-05
HUE052101T2 (hu) 2021-04-28
PT3352754T (pt) 2020-12-07
RS61239B1 (sr) 2021-01-29
EP3757107B1 (en) 2023-10-25
US10647726B2 (en) 2020-05-12
CA3025081A1 (en) 2017-12-28
EP3757107A1 (en) 2020-12-30
HRP20201905T1 (hr) 2021-01-22
WO2017223179A1 (en) 2017-12-28
LT3352754T (lt) 2021-02-25
MX2021014938A (es) 2022-01-24
CN109310674A (zh) 2019-02-05
US20190300543A1 (en) 2019-10-03
SG10202012188VA (en) 2021-01-28
US12077547B2 (en) 2024-09-03
DK3352754T3 (da) 2020-12-07
RU2019101194A (ru) 2020-07-23
JP7368419B2 (ja) 2023-10-24
JP2021130719A (ja) 2021-09-09
AU2017281082A1 (en) 2018-12-06
AU2023204218A1 (en) 2023-07-27
US20200283451A1 (en) 2020-09-10
ES2966094T3 (es) 2024-04-18
AU2021203801A1 (en) 2021-07-15
IL304979A (en) 2023-10-01
HUE064911T2 (hu) 2024-04-28
FI3757107T3 (fi) 2023-12-12
CN115160339A (zh) 2022-10-11
EP4316603A2 (en) 2024-02-07
US11498925B2 (en) 2022-11-15
RU2019101194A3 (OSRAM) 2020-08-31
IL263631A (en) 2019-01-31
JP2023171614A (ja) 2023-12-01
HRP20231563T1 (hr) 2024-03-15
CN115160339B (zh) 2024-05-14
BR112018076244A2 (pt) 2019-03-26
LT3757107T (lt) 2023-12-11
SI3757107T1 (sl) 2024-02-29
US10150779B2 (en) 2018-12-11
MX391561B (es) 2025-03-21
CN109310674B (zh) 2022-07-08
DK3757107T3 (da) 2023-11-27
EP3352754A1 (en) 2018-08-01
MX2018016122A (es) 2019-08-01
EP3352754B1 (en) 2020-09-02
SG11201810642XA (en) 2019-01-30
AU2021203801B2 (en) 2023-04-06
US20250163073A1 (en) 2025-05-22
IL283809A (en) 2021-07-29
HK1259379A1 (en) 2019-11-29
JP6895464B2 (ja) 2021-06-30
PL3757107T3 (pl) 2024-03-18
NZ748506A (en) 2025-07-25
EP4316603A3 (en) 2024-04-17
JP2025124733A (ja) 2025-08-26
JP7688681B2 (ja) 2025-06-04
US10870658B2 (en) 2020-12-22
ES2836500T3 (es) 2021-06-25
IL263631B (en) 2021-07-29
AU2023204218B2 (en) 2025-09-11
ZA201808506B (en) 2020-05-27
US20180237451A1 (en) 2018-08-23
SI3352754T1 (sl) 2021-03-31
PT3757107T (pt) 2023-12-14
IL283809B1 (en) 2023-09-01
US20210284652A1 (en) 2021-09-16
EP3352754A4 (en) 2019-04-17
JP2019518779A (ja) 2019-07-04
IL283809B2 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
AU2021203801B2 (en) Aldose reductase inhibitors and methods of use thereof
US11730737B2 (en) Aldose reductase inhibitors and uses thereof
CA2804640C (en) Aldose reductase inhibitors and uses thereof
HK40105726A (en) 4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
HK40044237A (en) 4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
HK40044237B (en) 4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
RU2795195C2 (ru) Ингибиторы альдозоредуктазы и способы их применения
HK1259379B (en) Aldose reductase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)